Germany's IQWiG finds some benefit for Pfizer orphan drug Vyndaqel

11 April 2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed Vyndaqel (tafamidis), a treatment for a rate neurological disorder the pharma behemoth Pfizer (NYSE: PFE), at the request of the Federal Joint Committee (G-BA), saying that it has found “a hint of a positive effect” of tafamidis on neurological degeneration.

Vyndaqel was approved by the European Commission last year for the treatment of transthyretin amyloidosis in adults (The Pharma Letter November 18, 2011). This rare disorder (orphan disease) is caused by a defective gene and is associated with progressive nerve damage (neurological degeneration) that tafamidis is supposed to delay, the IQWiG noted.

Tafamidis compared with "best supportive care"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK